Bellerophon Therapeutics is a clinical-stage therapeutics company focused on developing products for the treatment of cardiopulmonary diseases. The company's focus is on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH) using its proprietary pulsatile nitric oxide delivery platform, INOpulse. The company is developing INOpulse for the treatment of pulmonary hypertension associated with interstitial lung disease, which includes PH associated with idiopathic pulmonary fibrosis as well as other pulmonary fibrosing diseases. The company also initiated development of INOpulse for the treatment of PH associated with Sarcoidosis.

Champions Oncology is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company's TumorGraft Technology Platform is an approach to personalizing cancer care. The company provides solutions for two consumer groups: Translational Oncology Solutions, which provides a technology platform to pharmaceutical and biotechnology companies using proprietary TumorGraft studies; and Personalized Oncology Solutions, which assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services.

Citi Trends is a retailer of fashion apparel and accessories for the entire family. The company also provides a variety of products from less recognized brands and a lesser amount representing private label products under its brands. The company's merchandise includes apparel, accessories and home. Within apparel, the company provides fashion sportswear for men, women and children, including offerings for newborns, infants, toddlers, boys and girls. Accessories include handbags, jewelry, footwear, belts, intimate apparel, scrubs and sleepwear. Home includes functional bedroom, bathroom and kitchen products, as well as beauty and toys.

Funko is holding company. Through its subsidiaries, the company is a pop culture consumer products company. The company sells various licensed pop culture consumer products featuring characters from a range of media and entertainment content, including movies, TV shows, video games, music and sports. The company's product categories include: Figures, which includes figures that celebrate pop culture icons in the form of stylized vinyl, blind-packed miniatures and action figures; and Other, which includes plush products that are soft-sculpt figures; apparel (including t-shirts and hats); homewares (including drinkware, party lights and other home accessories); and stylized bags, purses and wallets and board games.

Scholar Rock is a biopharmaceutical company. The company's primary product candidate, SRK-015, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. The company's second product candidate is SRK-181 and is being developed for the treatment of cancers resistant to checkpoint blockade therapies, such as anti-PD1 antibodies. The company's third antibody program targets the signaling of bone morphogenetic protein 6, another member of the TGF? superfamily, which is involved in a set of biological processes in various parts of the body.